Terapia hipolepemiante intensiva en el manejo del riesgo cardiovascular ateroesclerótico

• Attilio Rigotti R ^[1] ; Antonio Arteaga Ll ^[1] ; Alberto Maiz G ^[1]
  1. [1] Pontificia Universidad Católica de Chile

     Pontificia Universidad Católica de Chile

     Santiago, Chile

     
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 134, Nº. 5, 2006, págs. 641-648
• Idioma: español
• Títulos paralelos:
  • Intensive cholesterol lowering therapy to reduce cardiovascular risk
• Enlaces
  • Texto completo
• Resumen

  • Primary and secondary prevention trials have clearly demonstrated that lowering serum cholesterol levels with statins reduces the incidence of cardiovascular events. Recent studies plus post hoc analysis of previous clinical trials show that risk reduction is proportional to the magnitude of LDL cholesterol lowering. Therefore, new recommendations of the National Cholesterol Education Program (USA) have defined a category of patients with very high cardiovascular risk, who should achieve serum LDL cholesterol levels below 70 mg/dl. This proposal will require new and more efficient pharmacologic strategies to attain the increasingly strict therapeutic goals for LDL cholesterol. This article reviews the clinical studies that support the use of intensive lipid lowering therapy to reduce cardiovascular risk. An effective reduction of serum cholesterol can be obtained using statins in high doses or a combination of hypolipidemic drugs with different mechanisms of action